Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

Part of paid clinical trials in Sacramento, California.

Sponsor
University of California, Davis
Study ID
NCT06389123
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. — DRUG
    Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.

Study Details

This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.

Key Dates

Start date
Apr 1, 2024
Status verified
Apr 2026
Primary completion
Jul 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: [177Lu]Lu DOTA-ABM-5G single dose therapy study
    Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy.

Primary Outcome Measure

[68Ga]Ga DOTA-5G PET/CT imaging [ Time Frame: 2 hours from time of injection ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of California Davis Comprehensive Cancer CenterSacramentoCalifornia95817
Julie L Sutcliffe, PhD
[email protected]
916-734-5536

Find similar trials in Sacramento, CA

By research site
The University of California Davis Comprehensive Cancer Center· Sacramento, CA

Related Studies